Compare Ginkgo Bioworks Holdings Inc (DNA) vs 8x8 Inc (EGHT) Price & Performance

Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.

Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.

EGHT trades at $2.15, up 0.47% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $27.21M in 2025 but shows improving trends with revenue growth to $745M and a projected net profit of $5M in 2026. Recent news highlights cost-saving client wins and AI product growth, while analyst consensus is a Buy with a $19.77 price target, suggesting significant upside potential from current levels.

The outlook is cautiously optimistic, with earnings beats and projected profitability offering opportunity, but high debt and thin margins pose risks. Investor sentiment is mixed amid valuation concerns, yet institutional interest and strategic partnerships support a positive long-term view if execution improves.